ASS1 and lung adenocarcinoma: Lastly, to validate our finding in other types of cancer, ASS1 expression was assessed in subsets of renal cell carcinoma (RCC) and lung adenocarcinoma (LUAD), among which, Caki-1 and A549, even harbor wildtype p53 [66, 67], appeared to be ASS1-deficient (Fig. 4E).